PAFAH1B3 Predicts Poor Prognosis and Promotes Progression in Lung Adenocarcinoma

Suping Tang (ntdxsp@163.com)
Affiliated Hospital of Nantong University

Jun Ni
Affiliated Hospital of Nantong University

Bohua Chen
Affiliated Hospital of Nantong University

Fei Sun
Affiliated Hospital of Nantong University

Songshi Ni
Affiliated Hospital of Nantong University

Zhiyuan Tang
Affiliated Hospital of Nantong University

Research Article

Keywords: PAFAH1B3, LUAD, prognosis, EMT, immune infiltrates.

DOI: https://doi.org/10.21203/rs.3.rs-365578/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Recently, increasing evidence has indicated that platelet-activating factor acetylhydrolase 1b catalytic subunit 3 (PAFAH1B3) plays an important role in several cancers. However, the role in lung adenocarcinoma (LUAD) has not been reported until now.

Methods

Expression of PAFAH1B3 in LUAD was determined by Gene Expression Profiling Interactive Analysis (GEPIA), real-time PCR (RT-PCR), Western blot and Immunohistochemical (IHC) analysis. LUAD datasets with clinical information were obtained from The Cancer Genome Atlas Program (TCGA). Chi-square test was used to investigate the correlation between PAFAH1B3 expression and clinical parameters. Cox regression and Kaplan-Meier analysis were performed to analyzed the prognostic value of PAFAH1B3. CCK-8 assay, clone formation assay, transwell invasion assay and flow cytometry were conducted to detect cell proliferation, clone formation, invasion and cell cycle. Western blot was performed to detect epithelial-to-mesenchymal transition (EMT)-related markers. Immune Cell Abundance Identifier (ImmuneCellAI) was used to analyze the effect of PAFAH1B3 on immune cell infiltration.

Results

Our study showed that PAFAH1B3 was upregulated in LUAD, and silencing PAFAH1B3 suppressed cell proliferation, colony formation, invasion and increased the cell population in G0-G1 phases in vitro. In addition, tissue microarray IHC analysis showed that the PAFAH1B3 protein level was remarkably correlated with distant metastasis, TNM stage and clinical outcome. Furthermore, multivariate cox regression analysis based on TCGA-LUAD datasets and tissue microarray indicated that PAFAH1B3 was an independent prognostic risk factor for LUAD patients. Moreover, knockdown of PAFAH1B3 inhibited EMT in LUAD cells and PAFAH1B3 mRNA expression was correlated with immune infiltrates.

Conclusion

Our studies indicate that PAFAH1B3, a prognostic risk factor, promotes proliferation, invasion and EMT and affects immune infiltrates in LUAD.

Background

Lung cancer has become the most commonly diagnosed malignancy and is the leading cause of cancer-related mortality among all cancers.[1] Non-small-cell lung cancer (NSCLC) is the most common pathological type of lung cancer, accounting for 85% of all lung cancer cases. NSCLC mainly has three
subtypes: adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma, accounting for 40%, 25–30%, and 10–15% of all lung cancer cases, respectively.[2] Despite the fact that significant progress has been made in the early diagnosis, targeted therapy and immunotherapy of NSCLC in recent years, the reality is that the overall survival (OS) of lung adenocarcinoma (LUAD) is still low.[3, 4] Therefore, accurate diagnostic and prognostic markers and effective therapeutic targets and predictors of response to immunotherapy for LUAD are urgently needed.

Platelet-activating factor acetylhydrolases (PAF-AHs) are a group of structurally variable isoenzymes that can catalyze the hydrolysis of the sn-2 acetyl group of platelet-activating factor (PAF), which is a lipid mediator participating in various physical and pathological processes, such as apoptosis, angiogenesis, the inflammatory response, wound healing and tumor development.[5–7] PAF-AHs are divided into three types, plasma PAF-AH, intracellular PAF-AHI and PAF-AHII, among which PAF-AHI has been recently recognized as an oncogenic factor.[5]

Platelet-activating factor acetylhydrolase 1b catalytic subunit 3 (PAFAH1B3), is a protein-coding gene that encodes the 29 kDa catalytic subunit, namely, the α1 subunit of PAF-AHI.[8] Many studies have found that PAFAH1B3 plays an important role in various cancers. PAFAH1B3 is considered an oncogene and is upregulated in several cancers, including prostate cancer, melanoma, breast cancer and ovarian cancer.[9] P11, an inhibitor of PAFAH1B2 and PAFAH1B3, can impair the pathogenicity of these cancers.[9, 10] In addition, through metabolic profiling, PAFAH1B3 was found to be upregulated in breast carcinoma cells, and downregulation of PAFAH1B3 remarkably inhibited breast carcinoma cell proliferation, migration and invasion.[11] Moreover, PAFAH1B3 loss sensitizes acute lymphoblastic leukemia cells to dasatinib in vivo. [12] Furthermore, PAFAH1B3 is associated with clinical outcome and contributes to the progression of hypopharyngeal squamous cell carcinoma (HSCC).[13] However, no studies have confirmed the precise function of PAFAH1B3 in LUAD.

Tumor-infiltrating immune cells have been found to be correlated with the survival of patients with different solid tumors. There are many examples; for example, a previous study proved that tumor-infiltrating CD8+ T lymphocytes are a favorable factor in patients with breast cancer.[14] Similarly, higher numbers of tumor-associated macrophages have been proven to exacerbate tumor progression and be associated with worse clinical prognosis in multiple cancers.[15] Furthermore, the function of tumor-infiltrating B lymphocytes remains controversial, as some studies have shown that B cells have antitumor capacity, while others indicate that different immunosuppressive subtypes of B cells may exert protumoral effects.[16] However, the exact mechanism of immune infiltration in LUAD remains unknown.

Thus, in this study, we aimed to demonstrate the correlations between the PAFAH1B3 expression level and clinicopathological parameters and to confirm the potential of PAFAH1B3 as a prognostic biomarker in LUAD patients. We also attempted to identify the mechanism by which PAFAH1B3 suppresses the proliferation and invasion of human LUAD cells in vitro. Furthermore, we attempted to explain the relationship between PAFAH1B3 expression levels and epithelial-to-mesenchymal transition (EMT)-related
protein expression levels. Finally, we attempted to find the mechanism underlying the association between PAFAH1B3 and tumor immune infiltration.

**Materials And Methods**

**Patients samples**

The primary LUAD tissues and paired adjacent tissues were collected from patients undergoing surgical treatment with their written informed consent. The surgically removed tissues were immediately frozen in liquid nitrogen and stored at -80°C. This experiment was approved by the Ethics Committee of Affiliated Hospital of Nantong University.

**TCGA Data acquisition**

We downloaded LUAD RNA-seq and corresponding clinical data from the Cancer Genome Atlas (TCGA), including 59 normal samples and 535 tumor samples. Cases with missing information on age, survival information, T classification, N classification and TNM stage were excluded and 475 tumor cases were included in Cox regression analysis. 535 tumor samples were kept for ImmuCellAI to explore the influence of PAFAH1B3 on the immune microenvironment of LUAD.

**GEPIA**

Gene Expression Profiling Interactive Analysis (GEPIA) is a web server which uses a standard processing pipeline to analyze the RNA sequencing expression data from the TCGA and the GTEx projects, including 9,736 tumors and 8,587 normal samples. We used GEPIA to analyze PAFAH1B3 mRNA expression in LUAD tissues compared with normal lung tissues. We also conduct disease free survival (DFS) and overall survival (OS) analysis by using the “Survival” module of GEPIA.

**Immunohistochemical (IHC) analysis**

A lung adenocarcinoma tissue microarray was purchased from Superbioteck (Shanghai, China) and it contained 79 tumor tissues among which there were 77 paired adjacent-tumor tissues. All samples had been pathologically diagnosed as lung adenocarcinoma. After dewaxing and rehydrating, paraffin sections were treated with 3% hydrogen peroxide to eradicate endogenous peroxidase. The tissue sections were placed in the antigen repair solution and were boiled in a microwave oven for antigen repair retrieval. Then, 5%-10% goat serum was used to blocking nonspecific binding site and tissue sections were incubated with PAFAH1B3 antibody (invitrogen MA5-26672) overnight at 4°C. After, incubating with secondary antibody, diaminobenzidine (DAB) solution was used for immunohistochemical staining. Two independent-experienced pathologists evaluated staining intensity and percentage of positive cells of all tissue sections double blindly. The staining intensity is categorized into 4 levels: 0 (negative), 1 (weak), 2 (medium), and 3 (strong), percentage of positive tumor cells is categorized into 4 levels: 1 ((≤ 25 %)), 2 (26–50 %), 3 (51–75 %), and 4 (>75 %). Immunoreactive score (IRS) = staining intensity × percentage of
positive cells. Then the X-file software was used to divide the PAFAH1B3 protein expression into two categories (high expression and low expression). Here, IRS value>6 was considered as a high expression.

**Cell Culture**

Human bronchial epithelial cell line (16HBE) and Human LUAD cell lines (NCI-H1299, NCI-H1650, A549, SPC-A1) were all from Cell Bank of Chinese Academy of Science (Shanghai, China). 16HBE and LUAD cells grown at 37°C and 5% CO2 in DMEM (Biological Industries, Israel) and RPMI-1640 (Biological Industries, Israel), respectively, both of which were supplemented with 10 % FBS (Biological Industries, Israel), 100 U/mL penicillin (Beyotime, china) and 0.1mg/mL streptomycin (Beyotime, china).

**RNA isolation and real-time PCR (RT-PCR)**

Total RNA was isolated from cells with Trizol reagent (Invitrogen, USA) and reverse transcribed to cDNA using RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher, USA). cDNA were then amplified using FastStart Universal SYBR Green Master (ROX) (Roche, Switzerland) by ABI 7500 (Applied Biosystems, USA). GAPDH were used for normalization. The gene expression were quantified using the $2^{-\Delta \Delta C_t}$ method. The primer sequences are as follows: PAFAH1B3 F: 5'-CTGGGCTACACCTGTTTGC-3′, PAFAH1B3 R 5′-GGAGAGTTTAATGTTGTGGGAAGG-3′, GAPDH F: 5′-GAACGGGAAGCTCACTGG-3′, GAPDH R: 5′-GCCTGCTTCACCACCTTCT-3′.

**Western blotting**

To extract proteins, we treated cells or tissues with RIPA Lysis Buffer (Beyotime, China) containing phenylmethanesulfonyl fluoride (PMSF) (Beyotime, China). According to the protein concentration measured by the BCA kit (Beyotime, China), 20µg total protein was added to each well for protein separation by SDS-PAGE. Then the protein were transferred to PVDF membranes (Millipore, USA), blocked with 5 % nonfat milk and incubated with primary and secondary antibodies for immunoblotting. Finally, protein bands were detected by the ECL chemiluminescent substrate kit (Biosharp, china). The primary antibodies were: PAFAH1B3 rabbit monoclonal (1:1000, ab166906, Abcam), E-cadherin rabbit monoclonal (1:10000, ab40772, Abcam), N-cadherin rabbit monoclonal (1:5000, ab76011, Abcam), Snail + Slug rabbit monoclonal (1:1000, ab85936, Abcam). GAPDH mouse monoclonal(1:100000, 60004-1-lg, Proteintech). The secondary antibodies were: anti-rabbit secondary antibody (HRP) (1:5000, AB0101, Abways Technology), anti-mouse secondary antibody (HRP) (1:2000, AB0102, Abways Technology).

**RNA interference and establishment of stable cell lines**

8*10^4 cells were seeded in 6-well plates overnight and transfected with lentivirus-mediated short hairpin RNA (shRNA) targeting PAFAH1B3 (Gene Pharma Co., Ltd shanghai, china). After 72 h, cells were cultured with medium containing 1.75 µg/ml puromycin (Beyotime, china) to establish stable PAFAH1B3-gene-knockdown cell lines. The efficiency of silencing PAFAH1B3 was detected by western blotting. A scrambled shRNA (shControl) was used as a control. The sequences of three lentivirus-mediated shRNAs targeting PAFAH1B3 were as follows: (shRNA1: 5′-gaTGGCACCACATCAGCCATCAT-3′, shRNA2: 5′-
cgACAGGTGAACGAGCTGGTA-3', shRNA3: 5’-gcAGGTGACTGGTGGCATCAA-3’) and the sequences of control shRNA: 5’-TTCTCCGAACGTGTCACGT-3’.

**Cell viability assay**

2*10^3 Cells were seeded in the 96-well plates. At 24h, 48h, 72h, 96h, the medium was removed and replaced with 110ul medium containing 10ul counting kit-8 (CCK-8) solution. After continuing to incubate for 2 hours, the absorbance at 450nm were measured.

**Colony formation assay**

1*10^3 were seeded in 6-well plates and the medium was changed every 3 days. After 9 days, the original medium was removed, the cells were washed twice with PBS and fixed with 4% paraformaldehyde for 20 minutes. Then cells were stained with crystal violet for 5 minutes. Finally, the cells were washed 3 times with PBS and pictured.

**Cell invasion assay**

The transwell chambers (8um, Corning, USA) were coated with 50ul of 1mg/mL Matrigel (356234, BD Sciences, USA). 5*10^4 cells were seeded in the upper chamber in serum-free medium while medium containing 20% FBS was added to the lower chamber. After 48 hours of incubation, non-invaded cells were swabbed off and invaded cells were fixed with 4% paraformaldehyde for 20 minutes and stained with 0.5% crystal violet for 5 minutes. Finally, cells were photographed (200×magnification) at five random views and counted with ImageJ.

**Cell cycle analysis**

Cells in 6-well plate at logarithmic growth stage were collected, washed with pre-cooled PBS and then fixed in pre-cooled 75% alcohol for 2 hours. Centrifuge at 1000g for 3-5min to precipitate the cells, carefully aspirate the ethanol and wash the cells again with PBS. Cells were stained with propidium iodide (PI) staining solution (US Everbright® Inc, china) containing RNase A. After incubating for 30 minutes at room temperature and protecting from light, the cell populations were detected by flow cytometry at 615 nm emission wavelength (BD Biosciences, USA) and analyzed with ModFit LT.

**ImmuCellAI**

Immune Cell Abundance Identifier (ImmuCellAI) (http://bioinfo.life.hust.edu.cn/web/ImmuCellAI/) is a web server which was applied to estimate the abundance of 24 immune infiltrating cells.[17] Compared to other methods, ImmuCellAI can accurately evaluate the abundance of immune cells especially on multiple T-cell subpopulations. According to PAFAH1B3 expression of the 535 LUAD samples from TCGA, the upper 1/3 samples were included into PAFAH1B3-high expression group while the lower 1/3 were included into the PAFAH1B3-low expression group. Then we upload the file to ImmuCellAI to analysis the immune infiltration level.

**Statistical analysis**
SPSS 16.0 software (IBM) and Graphpad Prism 7.0 (GraphPad Software) were used for all the statistical analysis. The data are shown as mean ± (standard deviation) SD from at least three independent experiments. Paired t-test was used for paired tissue samples. Student’s t-test was used for two groups. The chi-square test was used to analyze the relations between PAFAH1B3 and clinical features. Cox regression was used for univariate and multivariate analysis of prognostic factors. P < 0.05 was considered significant.

Results

PAFAH1B3 is upregulated in LUAD tissues and cell lines

To determine PAFAH1B3 expression in LUAD, we analyzed PAFAH1B3 mRNA expression data using GEPIA. We found that PAFAH1B3 mRNA was remarkably overexpressed in LUAD tissues (483 samples) compared with normal lung tissues (347 samples) (Additional file 1: Figure S1A, P < 0.05). To exclude individual differences, we further analyzed the mRNA expression of PAFAH1B3 in 57 paired lung tumor and normal tissues in TCGA LUAD datasets. We found that PAFAH1B3 was significantly upregulated in 52 lung tumor samples compared with their adjacent normal samples (Additional file 1: Figure S1B, P < 0.01).

To further determine whether PAFAH1B3 expression is indeed increased in LUAD, we first analyzed PAFAH1B3 protein levels in four human LUAD cell lines (H1299, A549, H1650 and SPCA1) and found that both the protein and mRNA expression levels of PAFAH1B3 were remarkably upregulated in A549, H1299 and H1650 cells compared with those in 16HBE cells (Fig. 1d, e, f, P < 0.01). Next, we quantified the PAFAH1B3 protein levels of 77 pairs of LUAD and nontumor tissue samples in a tissue microarray by immunohistochemistry (IHC) analysis. Our data showed that PAFAH1B3 expression was mainly localized in the cytoplasm of cancer cells, and the PAFAH1B3 protein level was prominently higher in 65 LUAD tissues than in the paired nontumor lung tissues (Fig. 1a, b, P < 0.01). We also collected eight pairs of paired primary LUAD tissues and nontumor lung tissues. Western blotting of the eight pairs of tumor tissues revealed that the PAFAH1B3 protein level was dramatically upregulated in the human primary LUAD tissues compared with that in the paired nontumor lung tissues (Fig. 1c, P < 0.01). The above results indicate that PAFAH1B3 is upregulated and may be an oncogene in human LUAD.

PAFAH1B3 has prognostic value in LUAD patients

To investigate whether PAFAH1B3 expression is associated with the clinical outcome of LUAD patients, we generated survival curves by using the “Survival” module of GEPIA. The results suggested that higher PAFAH1B3 expression correlated with shorter OS and disease-free survival (DFS) durations in LUAD patients (Additional file 1: Figure S2A, B, P < 0.01). Furthermore, according to the gene expression level of PAFAH1B3, we classified the 475 primary LUAD samples from TCGA into two categories by the median cutoff: PAFAH1B3 low (n = 237) and PAFAH1B3 high (n = 238). The univariate analysis showed that expression of PAFAH1B3 (HR = 1.497, P = 0.009, 95%CI = 1.018–2.023), primary tumor (HR = 1.690, P < 0.001, 95%CI = 1.336–2.139), lymph node metastasis (HR = 2.496, P < 0.001, 95%CI = 1.851–3.366) and
TNM stage (HR = 1.804, P < 0.001, 95%CI = 1.517–2.145) were significantly associated with the risk of death (Additional file 1: Table S1). In the multivariate analysis, PAFAH1B3 expression (HR = 1.416, P = 0.024, 95%CI = 1.047–1.915) and TNM stage (HR = 1.782, P < 0.001, 95%CI = 1.498–2.120) were independent prognostic factors for LUAD (Additional file 1: Table S1).

To further verify whether PAFAH1B3 expression is indeed correlated with poor clinical outcome in LUAD patients, the PAFAH1B3 protein levels in 79 LUAD patient tissue samples in a tissue microarray were quantified by IHC analysis. The staining intensity results of LUAD tissues are shown in Fig. 2a. According to the protein expression level of PAFAH1B3, the 79 LUAD patients were divided into two categories: PAFAH1B3 low (n = 25) and PAFAH1B3 high (n = 54). We analyzed the correlation between the PAFAH1B3 expression level and clinicopathologic parameters of patients with LUAD. The χ² test showed that the PAFAH1B3 protein expression level was remarkably positively correlated with distant metastasis (P = 0.021), vital status (P = 0.025) and TNM stage (P = 0.009). (Table 1). Furthermore, the univariate Cox regression analyses indicated that overexpression of PAFAH1B3 (HR = 2.240, P = 0.019, 95%CI = 1.141–4.394), advanced TNM stage (HR = 1.937, P < 0.001, 95%CI = 1.431–2.621), distant metastasis (HR = 6.014, P < 0.001, 95%CI = 3.086–11.72) and lymph node metastasis (HR = 3.389, P < 0.001, 95%CI = 1.824–6.297) were prominent negative prognostic factors for patients with LUAD (Table 2). Moreover, Kaplan–Meier survival curves demonstrated that high PAFAH1B3 protein level (log-rank P = 0.015) and advanced TNM stage (log-rank P < 0.001) were remarkably correlated with decreased OS in LUAD patients (Fig. 2b, c). Finally, the multivariate Cox regression analysis further confirmed PAFAH1B3 overexpression (HR = 1.991, P = 0.046, 95%CI = 1.011–3.921) and advanced TNM stage (HR = 1.884, P < 0.001, 95%CI = 1.390–2.552) as independent prognostic risk factors for OS in LUAD patients (Table 2).
### Table 1
Correlation between PAFAH1B3 expression and different clinicopathological Characteristics of clinical LUAD patients

| Characteristics                  | n   | PAFAH1B3               |      |      |      |      |
|----------------------------------|-----|------------------------|------|------|------|------|
|                                 |     | Low or no expression  | High expression | Pearson $\chi^2$ | P value |
| **Total**                        | 79  | 25(31.6)               | 54(68.4) |      |      |      |
| **Age(y)**                       |     |                        |      |      |      |      |
| <60                              | 39  | 13(33.3)               | 26(66.7) | 0.101 | 0.75  |      |
| ≥ 60                             | 40  | 12(30.0)               | 28(70.0) |      |      |      |
| **Gender**                       |     |                        |      |      |      |      |
| Male                             | 41  | 13(31.7)               | 28(68.3) | 0.000 | 0.990 |      |
| Female                           | 38  | 12(31.6)               | 26(68.4) |      |      |      |
| **Primary tumor**                |     |                        |      |      |      |      |
| T1                               | 20  | 5(25.0)                | 15(75.0) | 0.835 | 0.659 |      |
| T2                               | 38  | 14(36.8)               | 24(63.2) |      |      |      |
| T3 + T4                          | 18  | 6(33.3)                | 12(66.7) |      |      |      |
| Unknown                          | 3   | 0(0.0)                 | 3(100.0) |      |      |      |
| **Lymph node metastasis**        |     |                        |      |      |      |      |
| No                               | 38  | 15(39.5)               | 23(60.5) | 1.874 | 0.171 |      |
| Yes                              | 40  | 10(25.0)               | 30(75.0) |      |      |      |
| Unknown                          | 1   | 0(0.0)                 | 1(100.0) |      |      |      |
| **Distant metastasis**           |     |                        |      |      |      |      |
| No                               | 64  | 24(37.5)               | 40(62.5) | 5.341 | 0.021* |      |
| Yes                              | 15  | 1(6.7)                 | 14(93.3) |      |      |      |
| **TNM stage**                    |     |                        |      |      |      |      |
| stage I                          | 19  | 11(57.9)               | 8(42.1) | 11.47 | 0.009** |      |
| stage II                         | 19  | 4(21.1)                | 15(78.9) |      |      |      |
| stage III                        | 26  | 9(34.6)                | 17(65.4) |      |      |      |
| stage IV                         | 15  | 1(6.7)                 | 14(93.3) |      |      |      |

*P < 0.05, **P < 0.01
| Characteristics | n      | PAFAH1B3       |           |           |           |
|-----------------|--------|----------------|----------|----------|----------|
|                 |        | Low or no       | High      | Pearson 2 | P value  |
|                 |        | expression      | expression| χ^2      |          |
| Vital status    |        |                |          |          |          |
| Alive           | 30     | 14(46.7)        | 16(53.3) | 5.045    | 0.025*   |
| Dead            | 49     | 11(22.4)        | 38(77.6) |          |          |

*P < 0.05, **P < 0.01

### Table 2

Univariate and multivariate analysis of prognostic parameters of clinical LUAD patients using Cox regression

| Characteristics                  | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR                  | P value               | 95%CI     | HR      | P value | 95%CI    |
| Expression of PAFAH1B3 (low vs. high) | 2.240               | 0.019*                | 1.141–4.394 | 1.991   | 0.046*  | 1.011–3.921 |
| Age (years) (< 60 vs. ≥ 60)       | 1.394               | 0.248                 | 0.793–2.450 |         |         |          |
| Gender (male vs. female)          | 1.320               | 0.335                 | 0.751–2.320 |         |         |          |
| Primary tumor (T1 vs. T2 vs. T3 + T4) | 1.104               | 0.632                 | 0.736–1.658 |         |         |          |
| Lymph node metastasis (No vs. Yes) | 3.389               | 0.000***              | 1.824–6.297 |         |         |          |
| Distant metastasis (No vs. Yes)   | 6.014               | 0.000***              | 3.086–11.72 |         |         |          |
| TNM stage ([+|-] vs. [+]+)        | 1.937               | 0.000***              | 1.431–2.621 | 1.884   | 0.000*** | 1.390–2.552 |

TNM stage contains lymph node metastasis and distant metastasis, therefore, lymph node metastasis and distant metastasis was not included in the multivariate analysis.

CI: Confidence interval; HR: Hazard ratio. *P < 0.05, **P < 0.01, ***P < 0.001

Taken together, these results imply that high PAFAH1B3 expression correlates with advanced clinicopathological characteristics and poor prognosis in patients with LUAD and can be a prognostic factor in LUAD.
Efficiency of lentivirus-mediated PAFAH1B3 shRNA transfection in A549 and H1299 cells

PAFAH1B3 was expressed at the highest levels in A549 and H1299 cells (Fig. 1d, e, f, P < 0.01); therefore, the two cell lines were selected for PAFAH1B3 shRNA transfection. Western blot analysis showed that the PAFAH1B3 protein expression level was decreased dramatically in all three shRNA groups compared with the shControl group, but shRNA2 showed the most dramatic decrease in the PAFAH1B3 protein level (Fig. 3a, b, d, e, P < 0.01). Therefore, A549 shRNA2 cells and H1299 shRNA2 cells were selected for later experiments.

Knockdown of PAFAH1B3 inhibits proliferation and induces G0-G1 phase stagnation in LUAD cells

After stable PAFAH1B3 gene-knockdown cell lines were established, we conducted a CCK-8 assay to investigate the effect of PAFAH1B3 on LUAD cell proliferation. Silencing PAFAH1B3 dramatically reduced the growth rate of A549 and H1299 cells (Fig. 3c, f, P < 0.01). The results of the colony formation assay showed that shPAFAH1B3-transfected cells produced significantly smaller and fewer colonies than shControl cells (Fig. 3g, h, i, P < 0.01).

Moreover, we also used flow cytometry to study the effect of PAFAH1B3 on the cell cycle of LUAD cells. The cell population in the G0-G1 phases increased while the cell population in S phase decreased in LUAD cells transfected with PAFAH1B3 shRNA (Fig. 4a, b, c, d, P < 0.05). These results showed that silencing PAFAH1B3 suppressed the proliferation of LUAD cells by influencing the cell cycle.

Silencing PAFAH1B3 inhibits invasion and EMT in LUAD cells

PAFAH1B3 expression was correlated with distant metastasis of LUAD, and one characteristic of cancer metastasis is invasion. We performed a transwell assay to assess the number of cells passing through the chambers after 48 hours of culture. The invasiveness of LUAD cells was strongly suppressed in shPAFAH1B3-transfected cells compared with shControl cells (Fig. 5a, b, P < 0.05).

To further explore whether PAFAH1B3 promotes LUAD cell invasion through the EMT mechanism, we measured the protein level changes of E-cadherin, N-cadherin and Snail/Slug upon PAFAH1B3 downregulation. The results showed that the E-cadherin protein level was upregulated, while the N-cadherin protein level and Snail/Slug protein level were downregulated in shPAFAH1B3-transfected cells compared with shControl cells and parental cells (Fig. 5c, d, e, f, P < 0.01). These results show that PAFAH1B3 might facilitate the invasion of LUAD cells by influencing the EMT process via activation of snail slug.

Estimation of the abundances of infiltrating immune cells
To further explore the influence of PAFAH1B3 on the immune microenvironment of LUAD, we used ImmuCellAI to estimate the abundances of 24 infiltrating immune cells. The analysis showed that the infiltration score of the PAFAH1B3-high group was notably lower than that of the PAFAH1B3-low group (Fig. 6b, \( P < 0.01 \)). Effector memory T (Tem) cells, CD8 naive T cells, natural regulatory T cells (nTregs), \( \gamma \delta \) T cells, neutrophils and exhausted T (Tex) cells were notably enriched, while naive CD4 T cells, Tr1 cells, induced regulatory T cells (iTregs), cytotoxic T (Tc) cells, T follicular helper (Tfh) cells, mucosal-associated invariant T (MAIT) cells, dendritic cells (DCs), macrophages and CD4 T cells showed notably lower infiltration in the PAFAH1B3-high compared to the PAFAH1B3-low group (Fig. 6a). The results showed that high PAFAH1B3 expression was correlated with low levels of immune infiltration.

**Discussion**

PAFAH1B3, as one of the top 50 overexpressed metabolic enzymes in human cancers,[18] is involved in multiple types of tumors, but the roles of PAFAH1B3 in LUAD have not been clarified. In this research, we identified PAFAH1B3 as a promising oncogene in LUAD by analyzing public datasets and clinical samples, as well as by performing functional assays in vitro. We also found that PAFAH1B3 was correlated with immune infiltrates in LUAD.

First, we determined that PAFAH1B3 was significantly overexpressed in both LUAD tissues and LUAD cells. Then, we revealed that high PAFAH1B3 expression was significantly correlated with distant metastasis, advanced TNM stage and poor prognosis, indicating that PAFAH1B3 upregulation is positively related to LUAD progression. Furthermore, we confirmed PAFAH1B3 as an independent prognostic risk factor for LUAD through multivariate Cox regression analysis. Similarly, previous studies have confirmed that there is high expression of PAFAH1B3 in HSCC tissues by IHC analyses, and high expression of PAFAH1B3 is positively correlated with poor prognosis of HSCC patients.[13] Thus, we believe that PAFAH1B3 has potential clinical value in LUAD.

Next, we conducted in vitro experiments. We found that the suppression of PAFAH1B3 expression in LUAD cells inhibited clone formation and proliferation and caused G1 phase arrest in LUAD cells. These results indicate that PAFAH1B3 is a novel potential oncogene in LUAD. A previous study demonstrated that knockdown of PAFAH1B3 impaired the proliferation, migration, and invasiveness of breast carcinoma cells by elevating tumor-suppressing signaling lipids.[11] Moreover, PAFAH1B3 loss in vivo sensitized leukemia cells to tyrosine kinase inhibitor (TKI) treatment via the platelet activating factor (PAF)/platelet activating factor receptor (PAFR) signaling pathway, and PAF/PAFR has been found to exhibit beneficial effects in some cancers.[7, 12] PAFR suppresses the inflammation and neoplastic transformation induced by chemical carcinogens.[19] PAFAH1B3 might promote malignant progression of LUAD through the PAF/PAFR signaling pathway. More studies are needed to further study the changes in downstream signaling pathways and tumor signaling lipids that occur after silencing PAFAH1B3.
Invasion is one step of metastasis. Our results demonstrated that downregulation of PAFAH1B3 significantly inhibited the invasive ability of A549 and H1299 cells. As EMT is considered the first step of metastasis,[20] we further studied the mechanism through which PAFAH1B3 facilitates LUAD invasion. Through loss-of-function analysis in LUAD cells, we clearly demonstrated that PAFAH1B3 knockdown upregulated the protein expression of the epithelial marker E-cadherin but downregulated the expression of the mesenchymal marker N-cadherin and EMT-inducing transcription factors (Snail/Slug).

EMT is a process by which differentiated epithelial cells transition into motile mesenchymal cells, and it involves some key events, including loss of intercellular junctions, loss of cell polarity and acquisition of enhanced cell invasion and migration capacities.[21] Tumor cells that have undergone EMT may be resistant to chemotherapy and immunotherapy, acquire stem cell properties and escape immune surveillance.[22] EMT plays a central role in the development and progression of lung cancer, and targeting EMT signaling may be a new therapeutic strategy.[23]

EMT is characterized by loss of the epithelial marker E-cadherin and increased expression of the mesenchymal marker N-cadherin.[22] E-cadherin expression can be repressed by EMT-related transcription factors, including SNAIL, SLUG and TWIST. snail1 and slug, belonging to the snail family, are encoded by snail1 and snail2, respectively, and they can bind to the promoter region of E-cadherin and repress its transcription.[24, 25] Here, for the first time, we demonstrated that PAFAH1B3 might promote EMT by activating Snail/slug, which might lead to the downregulation of E-cadherin, resulting in enhanced invasion and mobility of LUAD cells. However, further studies of the pathways related to activation of Slug/snail by PAFAH1B3 and studies determining whether there are other transcription factors involved in the PAFAH1B3-mediated reduction in E-cadherin are needed.

Immune cells have been increasingly recognized to be involved in carcinogenesis and cancer progression in recent years; for example, tumor-infiltrating T cells in particular have been found to significantly influence prognosis and therapeutic outcomes.[26] We demonstrated that the infiltration score was notably lower in the PAFAH1B3-high group than in the PAFAH1B3-low group, indicating that increased expression of PAFAH1B3 was correlated with a lower immune infiltration level. Furthermore, our results showed that the PAFAH1B3-high expression group had significantly enriched tumor-promoting cells, such as nTregs, exhausted T cells and neutrophils. Neutrophils are considered the most significant predictor of poor survival in solid tumors.[27] In a mouse model of LUAD, neutrophil infiltration promoted tumor growth, increased the ability of cancer cells to metastasize and elevated the expression of snail, which in turn accelerated neutrophil accumulation.[28] These results are consistent with our results showing that neutrophils were upregulated in the PAFAH1B3 high-expression group and that snail was reduced when PAFAH1B3 was knocked down. Exhausted T cells can be observed in chronic infections and cancer, and elevated expression of inhibitory receptors on exhausted T cells facilitates CD8 + T cell failure and immune evasion.[29] nTregs, a subpopulation of T cells, are increased in the tumor microenvironment and are associated with poor survival in lung cancer.[30] In addition, we also found that CD4 + T cells, Tc cells, DCs, Tfh cells and MAIT cells were notably enriched in the PAFAH1B3-low group, which is consistent with their positive role in antitumor processes.[31–34] Tc cells are the main cells that participate in cancer
cell killing and elimination of tumors.[31] With the help of special DCs, CD4 + T cells can relay helpful signals to enhance the antitumor properties of cytotoxic T lymphocytes.[32] These results may partly account for the poor clinical outcomes of LUAD patients with PAFAH1B3 overexpression, and more experiments are needed to confirm the association between PAFAH1B3 expression and tumor-infiltrating immune cells.

According to the above experiments and public dataset analysis, we found that PAFAH1B3 plays an oncogenic role in the progression of LUAD and might be a reasonable target for LUAD therapy. Further validation of the tumorigenic effect of PAFAH1B3 in mice is needed. In the future, specific biological agents targeting PAFAH1B3 could be developed to benefit LUAD patients with high PAFAH1B3 expression.

**Conclusion**

In summary, we not only confirmed the oncogenic role of PAFAH1B3 in LUAD but also partially explained that PAFAH1B3 participates in LUAD progression through EMT; we also found a relationship between PAFAH1B3 expression and infiltrating immune cells. Our research establishes a solid theoretical foundation for further in-depth research regarding the mechanism by which PAFAH1B3 facilitates LUAD malignancy.

**Abbreviations**

PAFAH1B3
platelet-activating factor acetylhydrolase 1b catalytic subunit 3; LUAD: lung adenocarcinoma; GEPIA: Gene Expression Profiling Interactive Analysis; RT-PCR: real-time PCR; IHC: immunohistochemical; TCGA: the Cancer Genome Atlas Program; ImmuneCellAI: Immune Cell Abundance Identifier; EMT: epithelial-to-mesenchymal transition; NSCLC: non-small-cell lung cancer; OS: overall survival; DFS: disease free survival; PAF-AHs: platelet-activating factor acetylhydrolases; PAF: platelet-activating factor; HSCC: hypopharyngeal squamous cell carcinoma; Tc: cytotoxic T cells; Tex: exhausted T cells; Tr1: type 1 regulatory T cells; nTreg: natural regulatory T cells; iTreg: induced regulatory T cells; Th1: T helper cell type 1; Th2: T helper cell type 2; Th17: T helper cell type 17; Tfh: follicular helper T cells; Tcm: central memory T cells; Tem: effector memory T cells; NKT: natural killer T cell; MAIT: mucosal associated invariant T cells; DC: dendritic cells; NK: natural killer cells; tyrosine kinase inhibitor (TKI); platelet activating factor receptor (PAFR)

**Declarations**

**Ethics approval and consent to participate**

This study was officially recognized for it strictly carried out the procedures for care and use admitted by the Ethics Committee of the Affiliated Hospital of Nantong University (Ethic Number: 2018-K020). Written informed consent was obtained from each patient included in the study.
Consent for publication

Not applicable.

Competing interest

The authors declare that they have no competing interests.

Funding

This work was supported by Nantong Science and technology project (No. HS2018003, No. MS22020019), Primary Research and Development Project of Jiangsu Province (BE2018670).

Availability of data and materials

The datasets analyzed during the current study are available in the TCGA repository (https://cancergenome.nih.gov/).

Author Contributions

Songshi Ni and Zhiyuan Tang conceived and designed the study. Suping Tang performed the experiments and wrote the manuscript. Bohua Chen and Jun Ni conducted bioinformatics analysis. Fei Sun analyzed the data. All authors read and approved the final manuscript.

Acknowledgements

We acknowledge the human clinical biobank in Affiliated Hospital of Nantong University for offering tissue samples.

Author details

Suping Tang: ntdxtsp@163.com;
Jun Ni: nijun1000@126.com;
Fei Sun: zskamenashi@163.com;
Songshi Ni: jsntnss@163.com;
Zhiyuan Tang: tina2951@sina.com.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.
2. Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell death disease. 2018;9(2):117.

3. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Translational lung cancer research. 2018;7(3):220–33.

4. Herbst RS, Mogensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54.

5. Kono N, Arai H. Platelet-activating factor acetylhydrolases: An overview and update. Biochimica et biophysica acta Molecular cell biology of lipids. 2019;1864(6):922–31.

6. Lordan R, Tsoupas A, Zabetakis I. The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment. Advances in nutrition. 2019;10(1):148–64.

7. Lordan R, Tsoupas A, Zabetakis I, Demopoulos CA. Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives. Molecules 2019, 24(23).

8. McIntyre TM, Prescott SM, Stafforini DM. The emerging roles of PAF acetylhydrolase. Journal of lipid research. 2009;50 Suppl:255–9.

9. Kohnz RA, Mulvihill MM, Chang JW, Hsu KL, Sorrentino A, Cravatt BF, Bandyopadhyay S, Goga A, Nomura DK. Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer. ACS chemical biology. 2015;10(7):1624–30.

10. Chang JW, Zuhl AM, Speers AE, Niessen S, Brown SJ, Mulvihill MM, Fan YC, Spicer TP, Southern M, Scampavia L, et al: Selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survival. ACS chemical biology 2015, 10(4):925–932.

11. Mulvihill MM, Benjamin DI, Ji X, Le Scolan E, Louie SM, Shieh A, Green M, Narasimhalu T, Morris PJ, Luo K, et al. Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity. Chem Biol. 2014;21(7):831–40.

12. Fiedler ERC, Bhutkar A, Lawler E, Besada R, Hemann MT. In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1(+) BCP-ALL. Blood advances. 2018;2(11):1229–42.

13. Xu J, Zang Y, Cao S, Lei D, Pan X. Aberrant expression of PAFAH1B3 associates with poor prognosis and affects proliferation and aggressiveness in hypopharyngeal squamous cell carcinoma. OncoTargets therapy. 2019;12:2799–808.

14. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8 + lymphocytes predict clinical outcome in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(15):1949–55.

15. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014;105(1):1–8.

16. Tsou P, Katayama H, Ostrin EJ, Hanash SM. The Emerging Role of B Cells in Tumor Immunity. Cancer research. 2016;76(19):5597–601.
17. Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H, Guo AY. **ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy.** *Advanced science (Weinheim, Baden-Württemberg, Germany)* 2020, 7(7):1902880.

18. Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, Huang J, Asplund A, Mootha VK. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. *Nature communications.* 2014;5:3128.

19. Sahu RP, Kozman AA, Yao Y, DaSilva SC, Rezania S, Martel KC, Warren SJ, Travers JB, Konger RL. Loss of the platelet activating factor receptor in mice augments PMA-induced inflammation and cutaneous chemical carcinogenesis. *Carcinogenesis.* 2012;33(3):694–701.

20. Manshouri R, Coyaud E, Kundu ST, Peng DH, Stratton SA. **ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer.** 2019, 10(1):5125.

21. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. *Nature reviews Molecular cell biology.* 2014;15(3):178–96.

22. Ye X, Weinberg RA. Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. *Trends in cell biology.* 2015;25(11):675–86.

23. Otsuki Y, Saya H, Arima Y. **Prospects for new lung cancer treatments that target EMT signaling.** 2018, 247(3):462–472.

24. Bolós V, Peinado H, Pérez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. *Journal of cell science.* 2003;116(Pt 3):499–511.

25. Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. *Mol Cancer.* 2016;15:18.

26. Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. *Biomedicine pharmacotherapy = Biomedecine pharmacotherapie.* 2017;95:55–61.

27. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nature medicine.* 2015;21(8):938–45.

28. Faget J, Groeneveld S, Boivin G, Sankar M, Zangger N, Garcia M, Guex N, Zlobec I, Steiner L, Piersigilli A, et al. Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung Cancer. *Cell reports.* 2017;21(11):3190–204.

29. Reiser J, Banerjee A. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. *Journal of immunology research.* 2016;2016:8941260.

30. Zhang D, Chen Z, Wang DC, Wang X. Regulatory T cells and potential immunotherapeutic targets in lung cancer. *Cancer Metastasis Rev.* 2015;34(2):277–90.

31. Martínez-Lostao L, Anel A, Pardo J. How Do Cytotoxic Lymphocytes Kill Cancer Cells? Clinical cancer research: an official journal of the American Association for Cancer Research. 2015;21(22):5047–56.
32. Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4(+) T cell help in cancer immunology and immunotherapy. Nature reviews Immunology. 2018;18(10):635–47.

33. Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity. 2019;50(5):1132–48.

34. Rudak PT, Choi J, Haeryfar SMM. MAIT cell-mediated cytotoxicity: Roles in host defense and therapeutic potentials in infectious diseases and cancer. J Leukoc Biol. 2018;104(3):473–86.

Figures
PAFAH1B3 is up-regulated in LUAD tissues and cells. 

a) Representative immunohistochemical staining pictures for PAFAH1B3 in LUAD tissues and adjacent lung tissues. 

b) IHC analysis score of PAFAH1B3 protein expression in 77 paired tumor tissues in LUAD tissue microarray. 

c) PAFAH1B3 protein expression in eight paired LUAD tissues (T) and their adjacent nontumor tissues (N) by western blot. 

d-f) PAFAH1B3
protein expression in 16HBE and four LUAD cell lines by western blot. e PAFAH1B3 mRNA expression in 16HBE and four LUAD cell lines by RT-PCR. * P < 0.05, ** P < 0.01

Figure 2

High PAFAH1B3 expression in LUAD is associated with poor survival of LUAD patients. a Representative immunohistochemical staining pictures for PAFAH1B3 with different staining intensity in LUAD tissues. b Kaplan-Meier survive curve of differential PAFAH1B3 protein expression in 79 tumor tissues in LUAD
tissue microarray. c Kaplan-Meier survive curve of different TNM stage in 79 tumor tissues in LUAD tissue microarray.

Figure 3

PAFAH1B3 knockdown suppresses LUAD cell proliferation in vitro. a+b+d+e PAFAH1B3 protein level in three PAFAH1B3-shRNAs of A549 and H1299 cells compared with shControl and parental cells by western blot. c+f CCK8 assay and g+h+i Colony formation assay were performed to measure the proliferation ability in shPAFAH1B3-transfected cells compared to shControl or Basal cells. *P < 0.05, **P < 0.01
Figure 4

Silencing of PAFAH1B3 induces G1 phase arrest of LUAD cells. a+c Flow cytometry was conducted to detect the cell cycle changes in A549 and H1299 cells transfected with PAFAH1B3 shRNA2. b+d Statistical analysis showed increasing cell population in the G0-G1 phases and decreasing cell population in S phase. *P < 0.05
Knockdown of PAFAH1B3 inhibits invasive ability and EMT of LUAD cells. a+b Invasion assay were conducted in transwell chambers pre-coated with Matrigel. c+d+e+f Western blot was performed to detect the protein level of EMT related markers including E-cadherin, N-cadherin and SNAIL/SLUG in PAFAH1B3 silenced cells and control cells. *P < 0.05, **P < 0.01
Figure 6

Boxplots showing the relative abundances of 24 cell types among the PAFAH1B3-high expression group and PAFAH1B3-high expression group in LUAD dataset using ImmuCellAI. a The relative abundances of immune cells among the PAFAH1B3-high and PAFAH1B3-Low. b The Immune Infiltration Score among the PAFAH1B3-high and PAFAH1B3-Low. Tc: cytotoxic T cells; Tex: exhausted T cells; Tr1: type 1 regulatory T cells; nTreg: natural regulatory T cells; iTreg: induced regulatory T cells; Th1: T helper cell type 1; Th2: T helper cell type 2; Th17: T helper cell type 17; Tfh: follicular helper T cells; Tcm: central memory T cells; Tem: effector memory T cells; NKT: natural killer T cell; MAIT: mucosal associated invariant T cells; DC: dendritic cells; NK: natural killer cells. *P<0.05, **P<0.01.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- FigureS1.tif
- FigureS2.tif
- TableS1.xls